Leadership Team

"Affinity's Leadership Team is poised to deliver real results in real time."

Based in Cleveland, Ohio, Affinity was established in November 2010 by Drs. Julius Korley and Horst von Recum in collaboration with Case Western Reserve University. Recognizing the dynamic and rapidly changing medical and business environments we operate in, our staff is a vital part of Affinity’s accomplishments thus far. They are knowledgeable and extremely committed to Affinity’s continual ingenuity, reliability, and sustainability. Each staff member brings unique qualifications that are integral to Affinity’s continued success.

 

 

Dr. Julius Korley

Dr. Julius Korley is one of Affinity’s founders and the chief scientific officer of the company. Prior to co-founding Affinity, Dr. Korley gained valuable experience from being an early employee at Momenta Pharmaceuticals, a startup that matured into a publicly traded company. Because of his experience at Momenta—a once-small startup company that had an initial public offering after only three years — he knows of the insight, commitment and dedication required to see a project from start to maturation.

> Read more


 

Dr. Horst Von Recum

Co-founder of Affinity Therapeutics, Dr. Horst von Recum has more than 20 years of experience within the fields of chemical and biomedical engineering. A graduate of both Rice University (M.Ch.E) and the University of Utah (Ph.D.), Dr. von Recum spent his postdoctoral tenure conducting research at several of the country’s leading institutions, including MIT and Harvard Medical School.

> Read more


 

Dr. Sean Zuckerman

As senior research scientist for Affinity Therapeutics, Dr. Sean Zuckerman helps develop affinity-based drug delivery platforms into stand-alone products, generate in vivo data demonstrating product safety and efficacy, and write grants to obtain non-dilutive funding.

A graduate of the University of Wisconsin-Madison, he obtained his Ph.D. in biomedical engineering in 2008. Throughout his early academic career, as well as postdoctoral tenure, Dr. Zuckerman’s research has focused heavily on tissue engineering, utilization of adult stem cells for regenerative therapies, and drug delivery.

With more than nine years training and experience synthesizing polymeric materials and evaluating drug release and cellular response to materials, his innovative thinking and ingenuity have garnered him numerous honors and accolades within his field.

In addition to his current position with Affinity Therapeutics, he is also a senior research associate at Case Western Reserve University, working in its Center for Delivery of Molecules and Cells. Prior to joining Affinity Therapeutics, Dr. Zuckerman also served as clinical specialist at CardioInsight, helping develop 3-D non-invasive electrocardiographic mapping technology.


> view linkedin profile

> Read less


 

 

Dr. Thomas Facklam

Dr. Thomas Facklam has been a business consultant with Affinity since the company’s inception. Dr. Facklam has more than 25 years of experience in all phases of product development, manufacturing, business development and strategic management in the pharmaceutical, biotech, diagnostic, medical device and agri-food industries. Using his broad technology development and commercialization and business experience, he has assisted companies and organizations to develop efficient business and product development strategies.

> Read more
 

 
    ©2013 Affinity Therapeutics, LLC. All Rights Reserved.   Site Development by Webster Marketing Solutions, Ltd. Site Design by jing.